SARS-COV-2 INFECTION AND ITS SYMPTOMS AMONG COVID-19 VACCINATED AND UNVACCINATED HEALTH-CARE WORKERS

Authors

  • Vinod Kumar Maurya Department of Microbiology, Maharshi Vashishtha Autonomous State Medical College, Basti, Uttar Pradesh, India. https://orcid.org/0000-0001-9746-8299
  • Surabhi Shukla Department of Microbiology, Maharshi Vashishtha Autonomous State Medical College, Basti, Uttar Pradesh, India.
  • Archana Bora Department of Microbiology, Dr. Sampurnanand Medical College, Jodpur, Rajasthan, India https://orcid.org/0009-0009-1106-9402
  • Laxmi Rathore Department of Microbiology, Dr. S. N. Medical College, Jodhpur, Rajasthan, India https://orcid.org/0000-0003-0318-299X

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i11.48259

Keywords:

COVID-19 symptoms, COVID-19 vaccination, COVISHIELD, SARS-CoV-2, Time to recovery

Abstract

Objective: India’s national coronavirus disease 2019 (COVID-19) vaccination programs started during January 2021 and prioritized health-care workers (HCWs). In this study, we are attempting to measure post-vaccination product-specific (ChAdOx1_nCoV-19/COVISHIELD) COVID-19 vaccine effectiveness among vaccinated hospital HCWs and also to assess symptoms in HCWs with reverse transcription-polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection.

Methods: This is an online web-based cross-sectional study conducted in June 2021 among vaccinated HCWs, comparing SARS-CoV-2 incidence and symptoms. In this study, demographic data such as age, gender, and profession were collected. Other data collected were vaccination status at the time of infection, the gap between COVID-19 positivity and vaccination, symptoms, hospitalization, time to recovery, and previous positive history before vaccination.

Results: A total of 1685 HCWs were vaccinated with the COVISHIELD vaccine from January 16 to March 18, 2021. Out of 1685 HCWs, 82 (4.8%) were tested positive by RT-PCR after vaccination. Out of 82 positive HCWs, 84% experienced mild symptoms, 12.2% experienced moderate symptoms, and 3.7% had severe manifestations leading to hospitalization. Among these positive HCWs, 25.6% recovered within 7 days, 35.3% recovered in 7–10 days, 15.8% recovered in 11–14 days, and 23.1% recovered after 2 weeks from the 1st day of experiencing symptoms.

Conclusion: Although COVID-19 vaccination by COVISHIELD may not fully prevent from infection by SARS-CoV-2 or its different variants, majority of positive cases present with asymptomatic/mild symptoms. Post-vaccination-positive cases may also present with severe symptoms and require hospitalization.

Downloads

Download data is not yet available.

Author Biographies

Surabhi Shukla, Department of Microbiology, Maharshi Vashishtha Autonomous State Medical College, Basti, Uttar Pradesh, India.

 

 

Archana Bora, Department of Microbiology, Dr. Sampurnanand Medical College, Jodpur, Rajasthan, India

 

 

Laxmi Rathore, Department of Microbiology, Dr. S. N. Medical College, Jodhpur, Rajasthan, India

 

 

References

World Health Organization. Novel Coronavirus-nCoV: Situation Report; 2019. Available from: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports [Last accessed on 2022 May 19].

WHO. General’s Opening Remarks at the Media Briefing on COVID-19; 2020. Available from: https://www.who.int/directorgeneral/ speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020 [Last accessed on 2022 May 19].

WHO. Coronavirus (COVID-19) Dashboard. Available from: https:// covid19.who.int [Last accessed on 2022 May 19].

Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From hydroxychloroquine to ivermectin: What are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? J Travel Med 2021;28:taab005. doi: 10.1093/jtm/taab005, PMID 33480414

Ravikirti RR, Pattadar C, Raj R, Agarwal N, Biswas B, Majhi PK, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: A double-blind randomized placebo controlled trial in Eastern India. J Pharm Pharm Sci 2021; 24:343-50. doi: 10.18433/jpps32105

COVID-19 Vaccines. FDA. Available from: https://www.fda.gov/ emergency-preparedness-and-response/coronavirus-disease-2019- covid-19/covid-19-vaccines

WHO. Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process. Vaccine Guidance [Document]; 2021. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/status_ of_covid-19_vaccines_within_who_eul-pq_evaluation_process- 16june2021_final.pdf

Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier JS, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med 2021;384:1774-5. doi: 10.1056/ NEJMc2101927, PMID 33755376

CDC. SARS-CoV-2 Variant Classifications and Definitions. United States: Centers for Disease Control and Prevention; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html

COVID-19 Clinical Management: Living Guidance. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495-500. doi: 10.15585/mmwr.mm7013e3, PMID 33793460

Moore JP, Offit PA. SARS-CoV-2 vaccines and the growing threat of viral variants. JAMA 2021;325:821-2. doi: 10.1001/jama.2021.1114, PMID 33507218

Vahidy FS, Pan AP, Ahnstedt H, Munshi Y, Choi HA, Tiruneh Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One 2021;16:e0245556. doi: 10.1371/journal. pone.0245556, PMID 33439908

Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:6317. doi: 10.1038/s41467-020-19741-6, PMID 33298944

Published

07-11-2023

How to Cite

Maurya, V. K., S. Shukla, A. Bora, and L. Rathore. “SARS-COV-2 INFECTION AND ITS SYMPTOMS AMONG COVID-19 VACCINATED AND UNVACCINATED HEALTH-CARE WORKERS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 11, Nov. 2023, pp. 136-40, doi:10.22159/ajpcr.2023.v16i11.48259.

Issue

Section

Original Article(s)